The research for the truth of health qualities of cannabis is ever on the rise. Senators Dianne Feinstein of California, Chuck Grassley of Iowa, and Brian Schatz of Hawaii introduced the Cannabidiol and Marijuana Research Expansion Act. This act has been put forward to contribute to the manifestation of new ideas surrounding the benefits of cannabis and cannabis-derived compounds.
The bill itself is to provide a definite line in order to increase the speed and accuracy of cannabis studies. To do this, the bill will be giving allowance to perform more tests, studies and clinical research on all cannabis related compounds; CBD. According to Senator Feinstein:
“Many parents have had success treating their children with CBD oil, particularly for intractable epilepsy, but there are still too many unknowns when it comes to the medical use of marijuana and its compounds,”
“Current regulations make medical marijuana research difficult and stifles the development of new treatments. Our combined bill streamlines the research process and paves the way for marijuana-derived medications that are FDA-approved to keep consumers safe.”
Seems to be a calculated and scientifically safe way to continue and encourage research on cannabis. Obviously, allowing doctors and scientists to perform research gives them the ability to give a sound argument. Whether positive or negative, sound results are always a safer measure than a public trial. If the Food and Drug Administration (FDA) currently allowed all cannabis-derived compounds to be circulated among prescription medicine, then there could be catastrophic results. What if there were situations where it coincided with another drug and created very negative conditions for a patient prescribed such compounds? This would be the exact thing that everyone is attempting to avoid with this bill.
In order for anything to circulate through the medical world, there must first be research. The benefit of this research allows these medical professionals to safely prescribe medications without worry of it effecting their patients in a negative manner. Thankfully, this bill is doing just that. Senator Grassley said:
““The parents of children with severe epilepsy and other conditions are interested in cannabidiol to try to ease their children’s symptoms,”
“I understand their interest. Research is necessary to determine the potential medical value of cannabidiol, and wherever possible, the government should help facilitate the scientific research needed to give these parents the answers they need.”
Senator Grassley is obviously encouraging this necessary research because he himself sees the possible benefits of cannabis-derived compounds. There is no doubt there is positive results. People all over the world stand by such actions to neutralize or reduce their pain and anxiety without fail. All that is remaining to deal with is the fact that the law is the law. People are being limited by the budget and allotted time they are given to research into these cannabis derived compounds. Soon that will change though. According to Senator Schatz:
“The medical community agrees that we need more research to learn about marijuana’s potential health benefits, but our federal laws today are standing in the way of that inquiry,”
“Our bill will remove excessive barriers that make it difficult for researchers to study the effectiveness and safety of marijuana, and hopefully, give patients more treatment options.”
This bill provides a lot of information. If you wish to see the full bill text you can go here. A few of the many bill provisions are:
- “Amending the definition of marihuana in the Controlled Substances Act to exclude the synthetic equivalent of hemp-derived CBD that contains less than 0.3% THC.”
- “Allowing accredited medical and osteopathic schools, practitioners, research institutions, and manufacturers with a Schedule I registration to manufacture marihuana for their research.”
- “Allowing institutions appropriately registered with the DEA to import marihuana, marihuana seeds or CBD to conduct medical research for drug development.”
- “Allows physicians to discuss the potential harms and benefits of marihuana derivatives, including CBD, as a treatment with the legal guardian of the patient if the patient is a child. It also allows physicians to discuss the potential harms and benefits of both marihuana and its derivatives with adult patients.”
These are definitely motions that are going to define the new aged take on cannabis-derived compounds. Hopefully it will also allow for the FDA to find a manageable medium to define a limit or base area for amounts to be prescribed.
This bill is backed by a lot of organizations. For a full list you can check them out here. Some to note are the American Medical Association, American Psychological Association, Anxiety and Depression Association of America and the U.S. Pain Foundation. The American Medical Association has been around for a long time. They have played a crucial role in medicinal research and circulation. Their president, Patrice A. Harris, M.D., M.A., said:
“The AMA strongly supports the ‘Cannabidiol and Marijuana Research Expansion Act’ to enable legitimate research evaluating the potential efficacy and safety of medicines derived from cannabis. We applaud Sens. Feinstein, Grassley, and Schatz for their leadership in introducing this important legislation,”
But, these companies are just the tip of the iceberg. With over thirty different organizations backing this movement, it’s hard not to appreciate the hard work going towards improving the circulation of cannabis-derived compounds. Ideally medical research is quick. However, that is not always the case. This bill will at least hasten the actions of those involved in clinical research. Senators Feinstein, Grassley and Schatz aren’t the only officials behind this either. Senators Dick Durbin of Illinois, Amy Klobuchar of Minnesota, Thom Tillis of North Carolina, Tim Kaine of Virginia, Joni Ernst of Iowa and Kevin Cramer of North Dakota also support this bill. With all this backing, we can hope that we can rest our case and allow these organizations to do their job.
Concerned over whether the legality of marijuana was going to continue to stand in the way of medicine? Worry no more. These Senators have heard you. They are moving in a positive and calculative direction in hopes of ascertaining the future of safe and scientifically valid medicinal practices that pertain to cannabis and cannabis-derived compounds. Much to be learned. But, ever closer do we stride. I know I’m excited to learn of the increasing scientific information that this research will provide.
Interested in more news on Cannabis and its compounds? Check out the rest of our news feed that contains tons of information about CBD and Hemp news. If you just want to try out some CBD products then check out the CBDipedia superstore. CBDipedia contains a multitude of premium CBD products from Tinctures to Concentrates. If you’re still unsure, then feast your eyes on our CBD Facts page where we have plenty of information to guide you down your path to CBD tranquility.